



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

PASTAN and CHOWDHURY

Application No.: 09/581,345

Filed: September 27, 2000

For: ANTIBODIES, INCLUDING FV  
MOLECULES, AND  
IMMUNOCONJUGATES HAVING  
HIGH BINDING AFFINITY FOR  
MESOTHELIN AND METHODS FOR  
THEIR USE

Customer No.: 20350

Confirmation No. 2468

Examiner: Helms, Larry R.

Technology Center/Art Unit: 1642

DECLARATION OF DR. IRA H. PASTAN

**Mail Stop AF**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

I, DR. IRA H. PASTAN, hereby declare and state:

1. I am an inventor of the above-captioned patent application.
2. Figure 1 has been corrected to show the presence of an Isoleucine in place of a Leucine at position 21 of the sequence of the SS scFv antibody shown in the Figure.
3. The correction of the Figure is supported in the specification by a reference to a deposit "in the GenBank databank as Accession Number AF035617." Specification, at page 41, lines 10-11.
4. Attached to this Declaration is a copy of an email to me from my co-inventor, Dr. Partha Chowdhury. The email forwards a message from a Dr. Karen Clark, who is identified as being on GenBank's submissions staff.

**RECEIVED**  
DEC 08 2003  
TECH CENTER 1600/2900

5. The message from Dr. Clark indicates that Dr. Chowdhury updated the sequence submission accorded accession number AF035617 on December 1, 1999 to change nucleotide 61 from T to A. This changed the codon from "tta" to "ata". Pursuant to the standard genetic code, this changes the encoded amino acid residue from Leucine to Isoleucine, as indicated in Figure 1 as corrected.

6. Accordingly, the amendatory material (the correction of the amino acid shown at position 21 of Figure 1) consists of the same material incorporated by reference in the application.

I further declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statement and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that any such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signed: Ira H. Pastan

Ira H. Pastan, M.D.

Dated: Dec 1, 2003